Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in Leiomyosarcoma

September 7th 2021

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

ASTRO Guideline Provides Clarity on Radiation Use in Soft Tissue Sarcoma

August 30th 2021

The American Society for Radiation Oncology released a new clinical guideline, which was also published in Practical Radiation Oncology, outlined recommendations and patient selection for optimal radiation dosing, sequencing, and treatment planning for patients with soft tissue sarcoma.

Population-Based Data Show Amputations in Malignant Foot Neoplasms Correlate With Hispanics, Males

August 24th 2021

Amputations were found to be associated with Hispanic ethnicity and male sex in patients with neoplasms of the foot.

Dr. Van Tine on Outcomes With Catequentinib in Synovial Sarcoma

August 24th 2021

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Avapritinib Does Not Show PFS Benefit Over Regorafenib in Late-Line GIST, But Remains Active Option for Select Subset

August 6th 2021

Avapritinib did not improve progression-free survival vs regorafenib in patients with unresectable or metastatic gastrointestinal stromal tumors, but the agent continues to be the most active available option for a subset of patients with PDGFRA D842V–mutant disease.

FDA Grants Orphan Drug Designation to Sotigalimab for Soft Tissue Sarcoma

August 5th 2021

The FDA has granted an orphan drug designation to sotigalimab as a potential therapeutic option for patients with soft tissue sarcoma.

Chordomas: Rare, Indolent and Linked With Poor Outcomes, But Research Efforts Continue

July 29th 2021

Chordoma is described as an extremely rare sarcoma that attacks the bones of the spine and base of the skull.

Dr. Van Tine on the Rationale to Evaluate Catequentinib in Synovial Sarcoma

July 27th 2021

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

FDA Grants Priority Review to Nab-Sirolimus for Advanced Malignant PEComa

July 26th 2021

The FDA has granted priority review to a new drug application for the nanoparticle albumin-bound mTOR inhibitor nab-sirolimus for the treatment of patients with malignant perivascular epithelioid cell neoplasm.

Multimodality Approaches Improve Outcomes in Marginally-Inoperable Soft Tissue Sarcoma

July 26th 2021

A multimodality approach to treatment, which included sequential chemotherapy and radiation therapy followed by surgery, resulted in successful resection for most patients with marginally inoperable soft tissue sarcomas.

Randall Reviews the Advantages of Rotationplasty in Lower-Extremity Sarcomas

July 22nd 2021

R. Lor Randall, MD, FACS, discusses the advantages of rotationplasty for oncologic and non-oncologic indications in children and young adults.

MDM2 Inhibitor Milademetan Under Examination in Dedifferentiated Liposarcoma

July 21st 2021

The safety and efficacy of the oral MDM2 inhibitor milademetan is under investigation vs trabectedin, a current standard of care, in the treatment of patients with dedifferentiated liposarcoma as part of the recently initiated phase 3 MANTRA trial.

Treatment Patterns Differ by Non–Biologic Factors in Undifferentiated Pleomorphic Sarcoma

July 19th 2021

Treatment patterns differed for patients with metastatic undifferentiated pleomorphic sarcoma based on disease characteristics, age, race, combined household income, and treatment facility.

Delayed Treatment Associated With Unfavorable Outcomes in Ewing Sarcoma

July 15th 2021

Delays between biopsy and the start of induction chemotherapy, induction chemotherapy and surgery, and surgery and consolidation chemotherapy were associated with a poor prognosis in patients with localized Ewing sarcoma.

New Potential Therapeutics, Including BT169, Open Options in Osteosarcoma

July 13th 2021

Richard Gorlick, MD, expands on the process of identifying these novel targets in osteosarcoma and the clinical implications of this research for these patients.

Avapritinib Elicits Clinical Activity in Chinese Patients With PDGFRA D842V+ GIST

July 4th 2021

Avapritinib demonstrated encouraging clinical activity in Chinese patients with PDGFRA D842V–mutant gastrointestinal stromal in a bridging study of the NAVIGATOR trial.

Sarcoma, the “Forgotten Cancer”: Examining What’s Needed to Improve Care

June 24th 2021

Sarcomas, all together, have an incidence of less than 5/100,000 persons per year, according to the Surveillance, Epidemiology, and End Results Program. Compare that with breast cancer, which impacts 129.1/100,000 women per year, or lung cancer, which has an incidence of 53.1/100,000 persons per year

FDA Accepts Application for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

June 22nd 2021

The FDA has accepted for filing the resubmission of the new drug application for a unique formulation of sodium thiosulfate, for the prevention of ototoxicity that is induced by cisplatin chemotherapy in patients between the ages of 1 month and 18 years who have localized, nonmetastatic, solid tumors.

Randall Reviews Rare Incidence of and Challenges With Spinal Sarcomas

June 18th 2021

R. Lor Randall, MD, discusses the data from the population-based registry and provided more insight on prognostic factors and survival outcomes for patients with spinal sarcomas.

Oncology Leaves Its Mark on 2020 Research and Development Trends

June 16th 2021

Rates of clinical trial initiation, novel drug development, and collaborative research and development deals were oncology.